The accrual of patients to cancer clinical trials has been noted by a number of authors as a significant problem. Research to date has examined a range of patient and physician related factors that may account for the low accrual rate. Patient refusal as a reason for non-participation has been found by previous research to account for a significant proportion of patients who are not entered onto a trial. This project aimed to explore the differences in attitudes and psychological variables between patients who refused a clinical trial and those who consented.A cross sectional, single point, postal questionnaire design was employed. Patients who were medically eligible for current phase I, II or III cancer chemotherapy clinical trials receiv...
Abstract Background: Communication with patients contemplating Phase 1 cancer trial participation ...
BACKGROUND: Communication with patients contemplating Phase 1 cancer trial participation can be chal...
AbstractBackgroundClinical trials are critical to scientifically evaluate promising new therapies in...
The accrual of patients to cancer clinical trials has been noted by a number of authors as a signifi...
This paper reports on the reasons why patients agreed to or declined entry into randomized trials of...
Background: Recruitment of patients into randomised clinical trials (RCTs) is essential for treatmen...
Patients who agree and those who refuse clinical trial entry may differ in attitudes towards decisio...
The attitudes of women patients with cancer were explored when they were invited to participate in o...
BACKGROUND: Barriers to randomised clinical trial (RCT) recruitment include failure to identify eli...
Like any other speciality, palliative care needs a scientific foundation on which to base its practi...
BACKGROUND: barriers to randomised clinical trial (RCT) recruitment include failure to identify elig...
Background: Patients invited to take part in a clinical trial may evoke an archetype on which they m...
Background: Recruitment of patients into randomised clinical trials (RCTs) is essential for treatmen...
Introduction: Prospective clinical trials are essential to translate new therapy concepts or rather ...
Background: Patient accrual into cancer clinical trials remains at low levels. This survey elicited...
Abstract Background: Communication with patients contemplating Phase 1 cancer trial participation ...
BACKGROUND: Communication with patients contemplating Phase 1 cancer trial participation can be chal...
AbstractBackgroundClinical trials are critical to scientifically evaluate promising new therapies in...
The accrual of patients to cancer clinical trials has been noted by a number of authors as a signifi...
This paper reports on the reasons why patients agreed to or declined entry into randomized trials of...
Background: Recruitment of patients into randomised clinical trials (RCTs) is essential for treatmen...
Patients who agree and those who refuse clinical trial entry may differ in attitudes towards decisio...
The attitudes of women patients with cancer were explored when they were invited to participate in o...
BACKGROUND: Barriers to randomised clinical trial (RCT) recruitment include failure to identify eli...
Like any other speciality, palliative care needs a scientific foundation on which to base its practi...
BACKGROUND: barriers to randomised clinical trial (RCT) recruitment include failure to identify elig...
Background: Patients invited to take part in a clinical trial may evoke an archetype on which they m...
Background: Recruitment of patients into randomised clinical trials (RCTs) is essential for treatmen...
Introduction: Prospective clinical trials are essential to translate new therapy concepts or rather ...
Background: Patient accrual into cancer clinical trials remains at low levels. This survey elicited...
Abstract Background: Communication with patients contemplating Phase 1 cancer trial participation ...
BACKGROUND: Communication with patients contemplating Phase 1 cancer trial participation can be chal...
AbstractBackgroundClinical trials are critical to scientifically evaluate promising new therapies in...